Related Experiment Video
Updated: Jun 18, 2026
Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma
Published on: November 11, 2021
Marchantin C: a potential anti-invasion agent in glioma cells
Jie Shen1, Gang Li, Qinglin Liu
1Department of Neurosurgery, Qilu Hospital of Shandong University, Jinan, China.
Abstract:
Cancer cell migration is a leading cause of tumor recurrence and treatment failure. Previously, we reported that marchantin C exhibited promising antitumor activity by inducing microtubule depolymerization and apoptosis. In the present study, we investigated the effect of marchantin C on inhibition of migration in T98G and U87 cells. The scratch-induced migration, Boyden chamber and cell invasion assays were applied to determine that the migrating capacity and invasiveness of these glioma cell lines were inhibited when exposed to marchantin C at a low concentration. There are no obvious signs of apoptosis with this dose. Western blot analyses confirmed that MMP-2, a key role in cancer cell migration, was reduced after incubation with marchantin C in both glioma cell lines. In addition, signaling pathway investigations demonstrated that ERK/MAPK might be involved in MMP-2 downregulation, rather than the AKT/PI3K or JAK/STAT3 pathways. Moreover, marchantin C potently suppressed angiogenesis activity in vivo by CAM assay. This is the first study to demonstrate that marchantin C can inhibit glioma cell migration and invasiveness.
Insights
Marchantin C effectively inhibits glioma cell migration and invasion at low doses without causing apoptosis. This compound also suppresses angiogenesis, offering a potential new strategy for cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Cancer cell migration is a primary driver of tumor recurrence and treatment resistance.
- Marchantin C has previously demonstrated antitumor properties by inducing apoptosis and microtubule depolymerization.
- Glioma, a type of brain tumor, is characterized by aggressive cell migration and invasion.
Purpose of the Study:
- To investigate the effect of marchantin C on inhibiting the migration and invasion of T98G and U87 glioma cell lines.
- To elucidate the molecular mechanisms underlying marchantin C's anti-migratory effects.
- To assess the impact of marchantin C on angiogenesis.
Main Methods:
- Scratch-induced migration, Boyden chamber, and cell invasion assays were used to evaluate glioma cell motility.
- Western blot analysis was performed to assess the expression of matrix metalloproteinase-2 (MMP-2).
- Signaling pathway analysis (ERK/MAPK, AKT/PI3K, JAK/STAT3) and in vivo chick chorioallantoic membrane (CAM) assay for angiogenesis were conducted.
Main Results:
- Marchantin C significantly inhibited the migration and invasion of T98G and U87 cells at low concentrations, without inducing apoptosis.
- MMP-2 expression, crucial for cancer cell migration, was downregulated by marchantin C in both cell lines.
- The ERK/MAPK signaling pathway was implicated in MMP-2 downregulation, while AKT/PI3K and JAK/STAT3 pathways were not.
- Marchantin C demonstrated potent suppression of angiogenesis in vivo.
Conclusions:
- Marchantin C effectively inhibits glioma cell migration, invasion, and angiogenesis.
- The anti-migratory effect of marchantin C is mediated, in part, by the downregulation of MMP-2 via the ERK/MAPK pathway.
- Marchantin C represents a promising therapeutic agent for targeting glioma progression.
